Projektnummer

0070242

Zusammenfassung

The respiratory syncytial virus (RSV) is the causative agent of globally prevalent respiratory tract infections. Treatment options are limited: the standard-of-care consist of support with fluids and oxygen. To address this unmet medical need, the project team aims to develop innovative RSV fusion protein inhibitors with superior potency and resistance-breaking properties. In own preliminary work, the researchers have established an innovative multi-parametric workflow for the lead optimization of differentiated inhibitors. The chemical optimization is informed by structural biology an...